+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cytotoxic effect of interferon-alpha2a in combination with all-trans retinoic acid or cisplatin in human ovarian carcinoma cell lines



Cytotoxic effect of interferon-alpha2a in combination with all-trans retinoic acid or cisplatin in human ovarian carcinoma cell lines



Anti-Cancer Drugs 9(3): 229-238



Ovarian cancer has a poor prognosis due to the frequent appearance of a drug-resistant state. An alternative therapeutic approach may lie in combinations of conventional chemotherapeutic agents with new classes of drug, such as interferons (IFN) and differentiation-inducing agents. There is clinical evidence that both IFN-alpha2a-all-trans retinoic acid (ATRA) and IFN-alpha2a-cisplatin have significant activities on growth of malignant cells, cell differentiation or programmed cell death in solid tumors. In order to throw more light on the cellular basis of these findings and to optimize a schedule of such drug combinations, we examined the cytotoxic effects of various combinations on five human ovarian carcinoma cell lines. The experiments were based on a clonogenic assay on plastic. The different cell lines exhibited different sensitivities to the three drugs tested. Using the cell line most sensitive to these drugs, we then examined the effect of different sequences of two drug combinations. We observed a potentiation after pretreatment with ATRA followed by IFN-alpha2a and ATRA or after pretreatment with IFN-alpha2a followed by IFN-alpha2a and cisplatin. Using this schedule of administration, cytotoxic interactions between the two drugs were investigated by median effect analysis. Synergism or antagonism were observed depending on the intrinsic sensitivity of the cell line to the first drug and the concentrations used. The magnitude of these interactions was found to be influenced by the cellular sensitivity to the second drug. These results show that schedules of drug combinations are not easy to design and may help account for the various failures and the discrepant effects observed in clinical trials.

(PDF emailed within 1 workday: $29.90)

Accession: 008413946

Download citation: RISBibTeXText

PMID: 9625433


Related references

Antiproliferative effects of interferon alpha-2a in combination with all trans retinoic acid or cisplatin in human ovarian carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 293, 1996

The additive antiproliferative effect of all-trans retinoic acid and interferon-alpha2a on human cervical carcinoma cell lines is not associated with increased expression of retinoid receptors. Anti-Cancer Drugs 8(5): 522-528, 1997

Antiproliferative effects of alpha and beta interferon in combination with 5 fluorouracil cisplatin and cis and trans retinoic acid in two non small cell lung carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 32: 228, 1991

Modulation of cisplatin cytotoxicity by human recombinant interferon gamma and all trans-retinoic acid in four human ovarian cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 295, 1993

Enhancement of cisplatin cytotoxicity by all trans retinoic acid on human ovarian carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 293, 1995

Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. British Journal of Cancer 75(3): 333-340, 1997

Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines. Journal of Interferon Research 13(1): 25-32, 1993

Effect of the vitamin D analog , all-trans retinoic acid, and interferon alpha2a on cutaneous squamous cell carcinoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 39: 104, 1998

Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. European Journal of Cancer 36(18): 2411-2419, 2000

Differential effects of all-trans retinoic acid and docosahexaenoic acid on cisplatin-induced cytotoxicity and apoptosis in cisplatin sensitive and resistant human embryonal carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 401, 1996

Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: Relationship with induction of differentiation and retinoic acid receptor expression. International Journal of Cancer 56(5): 743-748, 1994

Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Research 21(2b): 1431-1437, 2001

Effect of all-trans retinoic acid on the apoptosis induced by cisplatin and Taxol in ovarian cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 23, 1996

Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin. European Archives of Oto-Rhino-Laryngology 270(2): 695-704, 2013

Anti-tumour activity of all-trans retinoic acid alone and in combination with IFN alpha-2b and cisplatin in human testicular cancer cell lines. Annals of Hematology 67(SUPPL ): A26, 1993